TP53 and glioblastoma: MDM2 amplification occurs in 14% and TP53 is mutated or deleted in 35% of glioblastomas.29 Moreover, AKT activation promotes cell cycle progression through phosphorylation and inhibition of cell cycle inhibitors p27 and p21, leading to stabilised cyclin D1/D3 and cell growth.